Question

In: Accounting

The following selected transactions relate to contingencies of Eastern Products Inc., which began operations in July...

The following selected transactions relate to contingencies of Eastern Products Inc., which began operations in July 2021. Eastern's fiscal year ends on December 31. Financial statements are published in April 2022.

  1. No customer accounts have been shown to be uncollectible as yet, but Eastern estimates that 3% of credit sales will eventually prove uncollectible. Sales were $300 million (all credit) for 2021.
  2. Eastern offers a one-year warranty against manufacturer's defects for all its products. Industry experience indicates that warranty costs will approximate 2% of sales. Actual warranty expenditures were $3.5 million in 2021 and were recorded as warranty expense when incurred.
  3. In December 2021, Eastern became aware of an engineering flaw in a product that poses a potential risk of injury. As a result, a product recall appears inevitable. This move would likely cost the company $1.5 million.
  4. In November 2021, the State of Vermont filed suit against Eastern, asking civil penalties and injunctive relief for violations of clean water laws. Eastern reached a settlement with state authorities to pay $4.2 million in penalties on February 3, 2022.
  5. Eastern is the plaintiff in a $40 million lawsuit filed against a customer for costs and lost profits from contracts rejected in 2021. The lawsuit is in final appeal and attorneys advise that it is virtually certain that Eastern will be awarded $30 million.

Required:
Prepare the appropriate journal entries that should be recorded as a result of each of these contingencies. (If no entry is required for a transaction/event, select "No journal entry required" in the first account field. Enter your answers in whole dollars.)

Solutions

Expert Solution

Date Account Title Debit Credit Remark
A No customer accounts have been shown to be uncollectible as yet, but Eastern estimates that 3% of credit sales will eventually prove uncollectible. Sales were $300 million (all credit) for 2021. 31-Dec-21 Bad Debts $          9,000,000 Accounting Estimates are used in accrual basis accounting to make the financial statements more complete. It usually anticipate events that have not yet occurred, but which are considered to be probable.
Provision for Doubtful Debts $               9,000,000 (300,000,000 X 3%)
B Eastern offers a one-year warranty against manufacturer's defects for all its products. Industry experience indicates that warranty costs will approximate 2% of sales. Actual warranty expenditures were $3.5 million in 2021 and were recorded as warranty expense when incurred. Date Account Title Debit Credit
31-Dec-21 Warranty Liability $          2,500,000 (2%*300000000-3500000)
Warranty Expense $               2,500,000
C In December 2021, Eastern became aware of an engineering flaw in a product that poses a potential risk of injury. As a result, a product recall appears inevitable. This move would likely cost the company $1.5 million. Date Account Title Debit Credit Adjustments must be made if the event provides evidence of conditions that existed at the end of the reporting period (the reporting date-31-Dec-2021).contingent liabilities should be recorded in the accounts when it is probable that the future event will occur and the amount of the liability can be reasonably estimated.
31-Dec-21 Injury Expenses $          2,500,000
Continge Liability-Liability on product $               2,500,000
D In November 2021, the State of Vermont filed suit against Eastern, asking civil penalties and injunctive relief for violations of clean water laws. Eastern reached a settlement with state authorities to pay $4.2 million in penalties on February 3, 2022. Date Account Title Debit Credit Adjustments must be made if the event provides evidence of conditions that existed at the end of the reporting period (the reporting date-31-Dec-2021).contingent liabilities should be recorded in the accounts when it is probable that the future event will occur and the amount of the liability can be reasonably estimated.
31-Dec-21 Penalty expenses $    4,200,000.00
State Authorities $         4,200,000.00
E Eastern is the plaintiff in a $40 million lawsuit filed against a customer for costs and lost profits from contracts rejected in 2021. The lawsuit is in final appeal and attorneys advise that it is virtually certain that Eastern will be awarded $30 million. Date Account Title Debit Credit Adjustments must be made if the event provides evidence of conditions that existed at the end of the reporting period (the reporting date-31-Dec-2021).A contingent asset becomes a realized (and therefore recordable) asset when the realization of income associated with it is virtually certain
31-Dec-21 Coningent Asset $        30,000,000
Accounts Receivable $            30,000,000

Related Solutions

The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in July 2021. Classical’s fiscal year ends on December 31. Financial statements are issued in April 2022. Classical’s products carry a one-year warranty against manufacturer’s defects. Based on previous experience, warranty costs are expected to approximate 3% of sales. Sales were $2.3 million (all credit) for 2021. Actual warranty expenditures were $20,100 and were recorded as warranty expense when incurred. Although no customer accounts have...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in July 2021. Classical’s fiscal year ends on December 31. Financial statements are issued in April 2022. Classical’s products carry a one-year warranty against manufacturer’s defects. Based on previous experience, warranty costs are expected to approximate 3% of sales. Sales were $4.0 million (all credit) for 2021. Actual warranty expenditures were $48,200 and were recorded as warranty expense when incurred. Although no customer accounts have...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in July 2021. Classical’s fiscal year ends on December 31. Financial statements are issued in April 2022. Classical’s products carry a one-year warranty against manufacturer’s defects. Based on previous experience, warranty costs are expected to approximate 4% of sales. Sales were $2.7 million (all credit) for 2021. Actual warranty expenditures were $43,500 and were recorded as warranty expense when incurred. Although no customer accounts have...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in July 2021. Classical’s fiscal year ends on December 31. Financial statements are issued in April 2022. Classical’s products carry a one-year warranty against manufacturer’s defects. Based on previous experience, warranty costs are expected to approximate 2% of sales. Sales were $3.3 million (all credit) for 2021. Actual warranty expenditures were $22,800 and were recorded as warranty expense when incurred. Although no customer accounts have...
Camden Biotechnology began operations in September 2016. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2016. The following selected transactions relate to liabilities of the company for September 2016 through March 2017. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2016 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $29,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...
Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2021 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $25,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $22...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $15,000,000 at the bank's prime rate (10.5% at the time). The company will pay no commitment fees. On October 1, borrowed $12...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $23,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $20...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $8,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $5...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $19,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $16...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT